directorsmr . domenico scaladr . thomas m. rinderknechtdr . martin nicklassonprof . daniel lewmr . steven d. skolskydr . thomas wernerboard committeesmanagement committee mr. ronald scottdr . g nter ditzingerprof . achim kaufholddr . laurenz kellenbergerms . heidi mcdaidmr . donato spotamr . david veitchextended management committeems . elizabeth rozekmr . adesh kauldr . josef k nzleefpia disclosure codetransparence des liens d int r tproductszevtera mabelio cresemba toctino microbiology testsportfolioceftobiproleisavuconazolebal101553bal3833alitretinoinresearchresearch strategyanti infectives researchoncology researchresearch center chinafeatured bugspathogens news and medianewsmedia contactscientific publicationsanti infectives20152014201320122011201020092008200720062005200420032002archiveoncology2015201420132012201120102009investor relationscorporate informationportfoliocorporate governancenews and mediafinancial reportsshare informationinvestors calendarannual general meetinginvestor relations contactnews subscriptioncareerscontact uscorporatehow to find usinvestor relations mediahuman resourcescollaborations home search go go to half year report 2016 stock information link to share information basilea pharmaceutica ltd. is headquartered in basel switzerland and listed on the six swiss exchange six bsln . it focuses on products that address increasing resistance and non response to current treatment options in the therapeutic areas of bacterial infections fungal infections and cancer . the company uses the integrated research development and commercial operations of its subsidiary basilea pharmaceutica international ltd. to discover develop and commercialize innovative pharmaceutical products to meet the medical needs of patients with serious and potentially life threatening conditions . news language english german go tuesday september 20 . 2016 pdf download basilea announces distribution agreement with unimedic for cresemba isavuconazole and zevtera ceftobiprole in the nordic countries basel switzerland september 20 2016 basilea pharmaceutica ltd. six bsln announced today that basilea pharmaceutica international ltd. basilea has entered into a license and distribution agreement with unimedic pharma ab unimedic for basilea s antifungal cresemba isavuconazole and antibiotic zevtera ceftobiprole in the nordic countries including sweden denmark and norway and finland . more ... thursday september 15 . 2016 pdf download basilea announces partnership for antifungal isavuconazole in japan with asahi kasei pharma basilea grants asahi kasei pharma exclusive license to develop and commercialize isavuconazole in japan basilea eligible for upfront and milestone payments of up to chf 67 million and double digit royalties more ... tuesday september 13 . 2016 pdf download basilea announces supply distribution and license agreement with grupo biotoscana for cresemba isavuconazole and zevtera ceftobiprole in latin america basel switzerland september 13 2016 basilea pharmaceutica ltd. six bsln announced today that basilea pharmaceutica international ltd. basilea has entered into a supply distribution and license agreement with grupo biotoscana s.l. gbt for basilea s antifungal cresemba isavuconazole and antibiotic zevtera ceftobiprole in 19 countries in latin america including brazil mexico argentina and colombia . more ... tuesday september 06 . 2016 pdf download basilea starts continuous infusion phase 1 2a clinical study with oncology drug candidate bal101553 basel switzerland september 6 2016 basilea pharmaceutica ltd. six bsln announced today that the first patient has been dosed in a new phase 1 2a continuous infusion study with its tumor checkpoint controller bal101553 in patients with advanced solid cancers . continuous infusion with portable pumps is an established mode of drug administration used for the treatment of certain cancers . more ... 2016 basilea pharmaceutica ltd. imprintterms & privacy info printable version quick links investor calendar upcoming events news subscription press releases via e mail french sunshine act transparence des liens d int r t